Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

NCT02749708 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Study drug supply expired and could not be renewed.

Conditions

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG: IRX5183

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]